The United States Army Medical Research and Materiel Command (USAMRMC), Office of the Congressionally Directed Medical Research Programs (CDMRP) invites applications for funding for the FY05 Neurofibromatosis (NF) NF Consortium Development Site Award.
The Neurofibromatosis Research Program (NFRP) seeks to establish a consortium of exceptional investigators that will conceive, develop, and conduct collaborative pilot and Phase I and II clinical evaluations of promising new therapeutic agents or approaches for the management or treatment of neurofibromatosis type 1 (NF1). Two separate award mechanisms are being offered in FY05 to select consortium participants and fund the development of the consortium the NF Consortium Development Site Award and the NF Consortium Development Operations Center Award. Proposals for the NF Consortium Development Site Award are being requested in this program announcement. This mechanism will be used to select exceptional NF1 clinical research institutions to join the consortium. A consortium member institution (or site) is defined as a for-profit, nonprofit, public, or private institution or organization in which all personnel, expertise, facilities, and resources dedicated to the consortium are contained in a single building, complex, or campus. Selected sites will develop the full consortium in collaboration with the Operations Center, which will be selected and funded through the NF Consortium Development Operations Center Award. The NF Consortium Development Site Award will provide support to member institutions to establish the necessary collaborations for the consortium and develop clinical protocols that will be conducted by participating investigators. Recipients of the FY05 NF Consortium Development Site Award will be required to collaborate with one another and with the recipient of the FY05 NF Consortium Development Operations Center Award to submit a proposal, clinical protocols, and associated clinical documents to the FY06 NF Consortium Award mechanism. Funding for FY05 NF Consortium Development Site Awards can be requested for $30,000 for 1 year, inclusive of both direct and indirect costs. Up to $300,000 is available to fund the FY05 NF Consortium Development Site Awards. Depending on the number and quality of applications, it is anticipated that five to ten proposals will be funded. Investigators funded under the NF Consortium Development Site Award mechanism will be required to collaborate with other investigators funded under this mechanism and with the recipient of the FY05 NF Consortium Development Operations Center Award to submit a proposal, clinical protocols, and associated clinical documents to the FY06 NF Consortium Award mechanism. However, the FY06 NF Consortium Award will be open to all eligible consortia focused on NF1 clinical research. Please see announcement for complete details of this award mechanism.
Electronic submission is required. Proposals will be accepted only as PDF files submitted through the CDMRP eReceipt system. No paper copy submissions will be accepted. The CDMRP uses a two-tier review process for proposals: scientific peer review, followed by programmatic review. Details of both tiers of review can be found in the Full Text of Program Announcement.
Estimated timelines for the FY05 NF Consortium Development Site Award proposals are as follows: Full Proposal Submission Deadline: May 3, 2005, 5:00 p.m. Eastern Time; Peer Review: August 2005; Programmatic Review: October 2005; Award Start Date: Between December 2005 and March 2006.
For additional information or questions, please contact: Patricia A. Evans, Contracting/Grants Office, U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, phone: (301) 619-7354, Fax: (301) 619-6662, email: firstname.lastname@example.org
Who can apply:
Eligible functional categories:
Military Medical Research and Development
DOD FY05 Neurofibromatosis Consortium Development Site Award Announcement
If you have problems accessing the full announcement, please contact:
US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014